A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
about
Intestinal M cells: the fallible sentinels?Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines.Th immune response induced by H pylori vaccine with chitosan as adjuvant and its relation to immune protection.Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixedPulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses.Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin aCellobiose-coated poly(lactide-co-glycolide) particles loaded with diphtheria toxoid for per os immunization.Nanoparticles as carriers for nasal vaccine delivery.Carbon nanotubes for the delivery of therapeutic molecules.Starch microparticles as vaccine adjuvant.Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated reviewDevelopment of live-attenuated influenza vaccines against outbreaks of H5N1 influenza.Strategies for intranasal delivery of vaccinesTranscutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine.Respiratory nanoparticle-based vaccines and challenges associated with animal models and translationIs intranasal vaccination a feasible solution for tuberculosis?Chitin and Chitosan: Production and Application of Versatile Biomedical Nanomaterials.Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles.Chitosan-based systems for the delivery of vaccine antigens.Carrier mediated protein and peptide stabilization.Bioadhesive delivery systems for mucosal vaccine delivery.Chitosan-based delivery systems for mucosal vaccines.Delivery of antigens used for vaccination: recent advances and challenges.Advances in chitosan-based drug delivery vehicles.Nasal-nanotechnology: revolution for efficient therapeutics delivery.Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.Heat-induced transcription of diphtheria toxin A or its variants, CRM176 and CRM197: implications for pancreatic cancer gene therapy.CriticalSorb™: enabling systemic delivery of macromolecules via the nasal route.Intranasal immunization with chitosan/pCAGGS-flaA nanoparticles inhibits Campylobacter jejuni in a White Leghorn model.Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge.Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes.Chitosan-plasmid nanoparticle formulations for IM and SC delivery of recombinant FGF-2 and PDGF-BB or generation of antibodies.Intranasal immunization with dry powder vaccines.Adjuvant synergy: the effects of nasal coadministration of adjuvants.Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs.Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform.
P2860
Q30050457-938CAFFD-840D-4D07-BA45-AC9C3DCC73D8Q34033764-DDE84C9B-3039-489F-A750-E3F3E25696C3Q34099129-F850F37E-21CF-4653-8394-7600D9618B14Q34194667-B57662C3-81DF-498F-BD67-02B4A6414DE6Q34293599-D5EEFD21-D155-4524-8841-E8AA794168A7Q34581660-27B7117F-7A2C-42FC-95BC-D8E4C60AD614Q35539544-2E006B7B-09F1-46F4-9C21-00A2913D8D98Q36124952-38C95816-4B92-4846-A82E-DB912DD08CA9Q36316616-CF3A6E83-BF23-425C-8AC3-B2F2573D8C42Q36316814-887038FF-CE31-4AA2-B6D5-698A99597E03Q36477627-E5883202-A55A-4796-BDAE-0A9B4DFF2F3CQ36482772-77657E03-B902-426A-86B1-BD4FF427CE24Q36514771-D6F0F33F-C622-484C-84EF-6D84AD1E4D2FQ36539669-0AFF81F9-3070-4DDB-AE35-679A766B7C2BQ36598433-9EBDB262-527A-42C9-8E07-7317BFDAF708Q37316013-DBF5A0AB-B470-4DB4-8E43-587AA493995FQ37392189-69083FE5-03E7-47EB-8262-D1EF6B684882Q37473416-65A1C6E0-AC18-4B7F-8B65-E9BF84A5A27DQ37524050-215F0855-2204-44C4-98DB-F24F5E9F6280Q37794158-E247E69B-7CAA-4E81-A56D-296187D14504Q37805519-483205E9-3A4F-46CB-8AFA-9B8C3C0E92EFQ38019583-CB8364D5-6E10-4844-8D98-1C4AF9346ACBQ38028969-FEECF837-7D3F-4788-BFA5-5DCBEA3B091BQ38091630-C2CE6DB8-0F6C-45A8-B776-D0A89DE6BA0DQ38217878-506AC7EA-C236-428C-9A49-2082F2E573DEQ38941665-96F40C90-4B4C-4E9E-99C4-9888BA429A9CQ39824358-8717225B-38F5-4671-92AC-ED17F6BD5D7EQ41196267-EB6CC76B-3271-47B2-8E83-C6C6238E7738Q41879270-F24728AD-2DD8-47B7-BAD8-DA7E086712E5Q43731325-AF93C533-6EA8-4371-A5C3-FE1D3DB7A865Q45868438-55F16557-B360-489A-806C-2A361F90C111Q45885233-EE943CD2-0FCE-4854-B6E2-89666AB7AEFEQ47584590-45B55440-53B0-433D-BA59-0496795BD5E2Q51996299-A37EA482-2B10-4B34-8659-8BDACCD63490Q54209314-D12E3525-792F-48C4-8A7F-2C1DFE527156Q54474177-5421B1DB-3FBE-45A5-9399-9204A50F73BE
P2860
A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
A mucosal vaccine against diph ...... nses following nasal delivery.
@en
A mucosal vaccine against diphtheria: formulation of cross reacting material
@nl
type
label
A mucosal vaccine against diph ...... nses following nasal delivery.
@en
A mucosal vaccine against diphtheria: formulation of cross reacting material
@nl
prefLabel
A mucosal vaccine against diph ...... nses following nasal delivery.
@en
A mucosal vaccine against diphtheria: formulation of cross reacting material
@nl
P2093
P1433
P1476
A mucosal vaccine against diph ...... nses following nasal delivery.
@en
P2093
D O'Connor
E A McNeela
I Jabbal-Gill
R Rappuoli
P304
P356
10.1016/S0264-410X(00)00309-1
P407
P577
2000-12-01T00:00:00Z